Cardiomyopathy Trial, Recruiting NCT06542016 Sponsor: Shenzhen Second People's Hospital Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT06542016
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 or older, of any gender or ethnicity
  • People who have been diagnosed with stage 5 chronic kidney disease (the most advanced stage of kidney failure), based on established medical guidelines
  • People who are newly diagnosed with kidney failure and are planning to start regular dialysis (either hemodialysis or peritoneal dialysis), or people who are already receiving regular dialysis
  • People for whom valid contact details are available for follow-up, either for the patient or a family member
  • People who have signed a consent form and are able to complete a specific heart-related quality-of-life questionnaire (called the KCCQ)

Who may not be able to join:

  • People whose kidney problems developed suddenly (acute kidney injury), rather than over a long period
  • People with severe mental health conditions that would make it difficult to complete questionnaires
  • People who have had a heart attack, a coronary artery stent procedure, heart bypass surgery, or a pacemaker fitted within the past three months
  • People with certain specific types of heart disease, including a condition where protein builds up in the heart (cardiac amyloidosis), heart conditions present from birth (congenital heart disease), or diseases affecting the sac surrounding the heart (pericardial diseases)
  • People with ongoing long-term lung disease
  • People with serious underlying health conditions such as severe infections, cancer, or severe liver disease
  • People who are scheduled to receive a kidney transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: QiJun Wan, Shenzhen Second People's Hospital

Phone: +8613798309505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shenzhen Second People's Hospital
Registry
ClinicalTrials.gov
Start date
1 July 2024
Est. completion
1 May 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

All-cause mortality; Mortality from cardiovascular causes; Incidence of cardiovascular disease-related hospitalizations

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov